



HAL
open science

Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure

Sonia Shah, Albert Henry, Carolina Roselli, Honghuang Lin, Garðar Sveinbjörnsson, Ghazaleh Fatemifar, Åsa Hedman, Jemma B. Wilk, Michael Morley, Mark Chaffin, et al.

► To cite this version:

Sonia Shah, Albert Henry, Carolina Roselli, Honghuang Lin, Garðar Sveinbjörnsson, et al.. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. *Nature Communications*, 2020, 11 (1), pp.163. 10.1038/s41467-019-13690-5 . hal-02577541

HAL Id: hal-02577541

<https://hal.univ-lorraine.fr/hal-02577541>

Submitted on 15 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

ARTICLE

<https://doi.org/10.1038/s41467-019-13690-5>

OPEN

Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure

Sonia Shah  et al.[#]

Heart failure (HF) is a leading cause of morbidity and mortality worldwide. A small proportion of HF cases are attributable to monogenic cardiomyopathies and existing genome-wide association studies (GWAS) have yielded only limited insights, leaving the observed heritability of HF largely unexplained. We report results from a GWAS meta-analysis of HF comprising 47,309 cases and 930,014 controls. Twelve independent variants at 11 genomic loci are associated with HF, all of which demonstrate one or more associations with coronary artery disease (CAD), atrial fibrillation, or reduced left ventricular function, suggesting shared genetic aetiology. Functional analysis of non-CAD-associated loci implicate genes involved in cardiac development (*MYOZ1*, *SYNPO2L*), protein homeostasis (*BAG3*), and cellular senescence (*CDKN1A*). Mendelian randomisation analysis supports causal roles for several HF risk factors, and demonstrates CAD-independent effects for atrial fibrillation, body mass index, and hypertension. These findings extend our knowledge of the pathways underlying HF and may inform new therapeutic strategies.

[#]A full list of authors and their affiliations appears at the end of the paper.

Hear failure (HF) affects >30 million individuals worldwide and its prevalence is rising¹. HF-associated morbidity and mortality remain high despite therapeutic advances, with 5-year survival averaging ~50%². HF is a clinical syndrome defined by fluid congestion and exercise intolerance due to cardiac dysfunction³. HF results typically from myocardial disease with impairment of left ventricular (LV) function manifesting with either reduced or preserved ejection fraction. Several cardiovascular and systemic disorders are implicated as aetiological factors, most notably coronary artery disease (CAD), obesity and hypertension; multiple risk factors frequently co-occur and the contribution to aetiology has been challenging based on observational data alone^{1,4}. Monogenic hypertrophic and dilated cardiomyopathy (DCM) syndromes are known causes of HF, although they account for a small proportion of disease burden⁵. HF is a complex disorder with an estimated heritability of ~26%⁶. Previous modest-sized genome-wide association studies (GWAS) of HF reported two loci, while studies of DCM have identified a few replicated loci^{7–11}. We hypothesised that a GWAS of HF with greater power would provide an opportunity for: (i) discovery of genetic variants modifying disease susceptibility in a range of comorbid contexts, both through subtype-specific and shared pathophysiological mechanisms, such as fluid congestion; and (ii) provide insights into aetiology by estimating the unconfounded causal contribution of observationally associated risk factors by Mendelian randomisation (MR) analysis¹².

Herein, we perform a large meta-analysis of GWAS of HF to identify disease associated genomic loci. We seek to relate HF-associated loci to putative effector genes through integrated analysis of expression data from disease-relevant tissues, including statistical colocalisation analysis. We evaluate the genetic evidence supporting a causal role for HF risk factors identified through observational studies using Mendelian randomisation and explore mediation of risk through conditional analysis. In summary, our study identifies additional HF risk variants, prioritises putative effector genes and provides a genetic appraisal of the putative causal role of observationally associated risk factors, contributing to our understanding of the pathophysiological basis of HF.

Results

Meta-analysis identifies 11 genomic loci associated with HF.

We conducted a GWAS comprising 47,309 cases and 930,014 controls of European ancestry across 26 studies from the Heart Failure Molecular Epidemiology for Therapeutic Targets (HERMES) Consortium. The study sample comprised both population cohorts (17 studies, 38,780 HF cases, 893,657 controls) and case-control samples (9 studies, 8,529 cases, 36,357 controls; see Supplementary Notes 2 and 3 for a detailed description of the included studies). Genotype data were imputed to either the 1000 Genomes Project (60%), Haplotype Reference Consortium (35%) or study-specific reference panels (5%). We performed a fixed-effect inverse variance-weighted (IVW) meta-analysis relating 8,281,262 common and low-frequency variants (minor allele frequency (MAF) > 1%) to HF risk (Fig. 1). We identified 12 independent genetic variants, at 11 loci associated with HF at genome-wide significance ($P < 5 \times 10^{-8}$), including 10 loci not previously reported for HF (Fig. 2, Table 1). The quantile–quantile, regional association plots and study-specific effects for each independent variant are shown in Supplementary Figs. 1–3. We replicated two previously reported associations for HF and three of four loci for DCM (Bonferroni-corrected $P < 0.05$; Supplementary Data 1). Using linkage disequilibrium score regression (LDSC)¹³, we estimated the heritability of HF in UK




Fig. 1 Study design and analysis workflow. Overview of study design to identify and characterise heart failure-associated risk loci and for secondary cross-trait genome-wide analyses. GWAS, genome-wide association study; QTL, quantitative trait locus; MAGMA, Multi-marker Analysis of GenoMic Annotation; SNP, single-nucleotide polymorphism; mtCOJO, multi-trait-based conditional and joint analysis.

Biobank (h_g^2) on the liability scale, as 0.088 (s.e. = 0.013), based on an estimated disease prevalence of 2.5%¹⁴.

Phenotypic effects of HF-associated variants.

Next, we investigated associations between the identified loci and other traits that may provide insights into aetiology. First, we queried the NHGRI-EBI GWAS Catalog¹⁵ and a large database of genetic associations in UK Biobank (<http://www.nealelab.is/uk-biobank>), and identified several biomarker and disease associations at each locus (Supplementary Data 2 and 3). Second, we tested for associations of identified loci with ten known HF risk factors, including cardiac structure and function measures, using GWAS summary data (Supplementary Data 4)^{16–23}. Six sentinel variants were associated with CAD, including established loci, such as 9p21/CDKN2B-AS1 and LPA¹⁸. Four variants were associated with atrial fibrillation (AF), a common antecedent and sequela of HF²⁴. To estimate whether the HF risk effects were mediated wholly or in part by risk factors upstream of HF (e.g., CAD), we conditioned HF GWAS summary statistics on nine HF risk factors using Multi-trait Conditional and Joint Analysis (mtCOJO)²⁵ (Supplementary Data 5). Conditioning on AF attenuated the HF risk effect by >50% for the PITX2/FAM241A locus but not other AF-associated loci (KLHL3, SYNPO2L/AGAP5), conditioning on CAD fully attenuated effects for two of the six CAD loci (LPA, 9p21/CDKN2B-AS1) and conditioning on body mass index (BMI) ablated the effect of the FTO locus (Supplementary Fig. 4, Supplementary Data 5). Next, we performed hierarchical agglomerative clustering of loci based on cross-trait associations to identify groups related to HF subtypes (Fig. 3). Among HF loci not associated with CAD, a group of four clustered together, of which two (KLHL3 and SYNPO2L/AGAP5) were associated with AF and two (BAG3 and CDKN1A) with reduced LV systolic function (fractional shortening (FS); Bonferroni-corrected $P < 0.05$); we highlight the results for these loci in our reporting of subsequent analyses to identify candidate genes. Notably, genetic




Fig. 2 Manhattan plot of genome-wide heart failure associations. The x-axis represents the genome in physical order; the y-axis shows $-\log_{10} P$ values for individual variant association with heart failure risk from the meta-analysis ($n = 977,323$). Suggestive associations at a significance level of $P < 1 \times 10^{-5}$ are indicated by the blue line, while genome-wide significance at $P < 5 \times 10^{-8}$ is indicated by the red line. Meta-analysis was performed using a fixed-effect inverse variance-weighted model. Independent genome-wide significant variants are annotated with the nearest gene(s).

associations with DCM at the *BAG3* locus have been reported previously^{10,11}.

Tissue-enrichment analysis. We performed gene-based association analyses using MAGMA²⁶ to identify tissues and aetiological pathways relevant to HF. Thirteen genes were associated with HF at genome-wide significance, of which four were located within 1 Mb of a sentinel HF variant and expressed in heart tissue (Supplementary Data 6). Tissue specificity analysis across 53 tissue types from the Genotype-Tissue Expression (GTEx) project identified the atrial appendage as the highest ranked tissue for gene expression enrichment, excluding reproductive organs (Supplementary Fig. 5). We sought to map candidate genes to the HF loci by assessing the functional consequences of sentinel variants (or their proxies) on gene expression, and protein structure/abundance using quantitative trait locus (QTL) analyses.

Variant effects on protein coding sequence. Since the identified HF variants were located in non-coding regions, we investigated if sentinel variants were in linkage disequilibrium (LD, $r^2 > 0.8$) with non-synonymous variants with predicted deleterious effects. We identified a missense variant in *BAG3* (rs2234962; $r^2 = 0.99$ with sentinel variant rs17617337) associated previously with DCM and progression to HF, and three missense variants in *SYNP2L* (rs34163229, rs3812629 and rs60632610; all $r^2 > 0.9$ with sentinel variant rs4746140)^{10,11,27}. All four missense variants had Combined Annotation Dependent Depletion scores > 20 , suggesting deleterious effects (Supplementary Data 7).

Prioritisation of putative effector genes by expression analysis. We then sought to identify candidate genes for HF risk loci by assessing their effects on gene expression. Given that cardiac dysfunction defines HF and that HF-associated genes by MAGMA analysis were enriched in heart tissues, we first looked for expression quantitative trait loci (eQTL) in heart tissues (LV, left atrium, and RAA, right atrium auricular region) from the Myocardial Applied Genomics Network (MAGNet) and GTEx projects. Three of 12 variants were significantly associated with the expression of one or more genes located in *cis* in at least one heart tissue (Bonferroni-corrected $P < 0.05$; Supplementary Data 8). For several of the identified HF loci, extra-cardiac tissues are likely to be relevant; for example, liver is reported to mediate

effects of the LPA locus²⁸. To further explore these effects, we then analysed results from a large whole-blood eQTL dataset ($n = 31,684$) and found associations with *cis*-gene expression ($P < 5 \times 10^{-8}$) for 8 of 12 sentinel variants (Supplementary Table 1)²⁹. For most HF variants, heart eQTL associations were consistent with those for blood traits; however, for intronic HF sentinel variants in *BAG3*, *CDKN1A* and *KLHL3* we detected expression of the corresponding gene transcripts in blood only.

Next, to prioritise among candidate genes identified through eQTL associations, we estimated the posterior probability for a common causal variant underlying associations with gene expression and HF at each locus, by conducting pairwise Bayesian colocalisation analysis³⁰. We found evidence for colocalisation (posterior probability > 0.7) for *MYOZ1* and *SYNP2L* in heart, *PSRC1* and *ABO* in heart and blood; and *CDKN1A* in blood (Supplementary Data 8, Supplementary Table 1). *PSRC1* and *MYOZ1* were also implicated in a transcriptome-wide association analysis performed using predicted gene expression based on GTEx human atrial and ventricular expression reference data (Supplementary Table 2). Using serum pQTL data from the INTERVAL study ($N = 3,301$), we also identified significant concordant *cis* associations for *BAG3* and *ABO* (Supplementary Data 9)³¹.

The evidence linking candidate genes with HF risk loci is summarised in Supplementary Table 3, and candidate genes are described in Supplementary Note 1. At HF risk loci associated with reduced systolic function or AF, but not with CAD, the annotated functions of candidate genes related to myocardial disease processes, and traits that may influence clinical expressivity, such as renal sodium handling. For example, the sentinel variant at the *SYNP2L/AGAP5* locus was associated with expression of *MYOZ1* and *SYNP2L*, encoding two α -actinin binding Z-disc cardiac proteins. *MYOZ1* is a negative regulator of calcineurin signalling, a pathway linked to pathological hypertrophy^{32,33} and *SYNP2L* is implicated in cardiac development and sarcomere maintenance³⁴. The HF sentinel variant at the *BAG3* locus was in high LD with a non-synonymous variant associated previously with DCM¹¹, and was associated with decreased *cis*-gene expression in blood. *BAG3* encodes a Z-disc-associated protein that mediates selective macroautophagy and promotes cell survival through interaction with apoptosis regulator *BCL2*³⁵. *CDKN1A* encodes p21, a potent cell cycle inhibitor that mediates post-natal cardiomyocyte cell cycle arrest³⁶ and is implicated in *LMNA*-mediated cellular stress

Table 1 Variants associated with heart failure at genome-wide significance.

rsID	Chr	Position (hg19)	Nearest gene(s) ^a	Function	Risk/ref allele	RAF (%)	OR (95% CI)	P value	I ² _{HET}	P _{HET}
rs60240	1	109817838	CFLSR2	UTR3	C/T	0.79	1.06 (1.04-1.08)	3.25E-10	0	0.513
rs17042102	4	111668626	PITX2, FAM241A	Intergenic	A/G	0.12	1.12 (1.09-1.14)	5.71E-20	43.1	0.008
rs11745324	5	137012171	KLHL3	Intronic	G/A	0.77	1.05 (1.03-1.07)	2.35E-08	5.7	0.381
rs4135240	6	36647680	CDKN1A	Intronic	T/C	0.66	1.05 (1.03-1.07)	6.84E-09	43.8	0.009
rs55730499	6	161005610	LPA	Intronic	T/C	0.07	1.11 (1.08-1.14)	1.83E-11	21.1	0.164
rs140570886	6	161013013	LPA	Intronic	C/T	0.02	1.24 (1.16-1.3)	7.69E-11	24.8	0.133
rs1556516	9	22100176	9p21/CDKN2B-AS1	ncRNA	C/G	0.48	1.06 (1.05-1.08)	1.57E-15	12.8	0.269
rs600038	9	136151806	ABO, SURF1	Intergenic	C/T	0.21	1.06 (1.04-1.08)	3.68E-09	0	0.729
rs4746140	10	75417249	SYNPO2L, AGAP5	Intergenic	G/C	0.85	1.07 (1.05-1.09)	1.10E-09	9.7	0.319
rs17617337	10	121426884	BAG3	Intronic	C/T	0.78	1.06 (1.04-1.08)	3.65E-09	55	2.1E-4
rs4766578	12	111904371	ATXN2	Intronic	T/A	0.47	1.04 (1.03-1.06)	4.90E-08	10.6	0.308
rs56094641	16	53806453	FTO	Intronic	G/A	0.42	1.05 (1.03-1.06)	1.21E-08	17.4	0.215

The table shows the 12 independent variants associated with HF at the genome-wide significance level ($P < 5 \times 10^{-8}$) in the meta-analysis of 29 studies. Meta-analyses were carried out using an IVW fixed-effect approach. The I²_{HET} describes the percentage of variation across the 29 studies that is due to heterogeneity. P_{HET} was derived from a Cochran's Q-test (two-sided) for heterogeneity. Chr, chromosome; ncRNA, non-coding RNA; ref, reference; RAF, risk allele frequency; OR, odds ratio; CI, confidence intervals; HET, heterogeneity; I², I-squared. ^aNearest gene with a functional protein or RNA (e.g., anti-sense RNA) product that either overlaps with the sentinel variant, or for intergenic variants, the nearest genes up- and downstream, respectively (separated by comma).

responses³⁷. *KLHL3* is a negative regulator of the thiazide-sensitive Na⁺Cl⁻ cotransporter (*SLC12A3*) in the distal nephron; loss of function variants cause familial hyperkalaemic hypertension (FHHt) by increasing constitutive sodium and chloride resorption³⁸. The sentinel variant at this locus was associated with decreased gene expression and could predispose to sodium and fluid retention. Notably, thiazide diuretics inhibit *SLC12A3* to restore sodium and potassium homeostasis in FHHt and are effective treatments for preventing hypertensive HF³⁹.

Genetic appraisal of HF risk factors. Although many risk factors are associated with HF, only myocardial infarction and hypertension have an established causal role based on evidence from randomised controlled trials (RCTs)⁴⁰. Important questions remain about causality for other risk factors. For instance, type 2 diabetes (T2D) is a risk factor for HF, yet it is unclear if the association is mediated via CAD risk or by direct myocardial effects, which may have important preventative implications⁴¹. Accordingly, we investigated potential causal roles for modifiable HF risk factors, using GWAS summary data. First, we estimated the genetic correlation (r_g) between HF and 11 related traits, using bivariate LDSC. For eight of the eleven traits tested, we found evidence of shared additive genetic effects with estimates of r_g ranging from -0.25 to 0.67 (Supplementary Table 4). The estimated CAD-HF r_g was 0.67, suggesting 45% (r_g^2) of variation in genetic risk of HF is accounted for by common genetic variation shared with CAD, and that the remaining genetic variation is independent of CAD.

Next, we estimated the causal effects of the 11 HF risk factors using Generalised Summary-data-based Mendelian Randomisation, which accounts for pleiotropy by excluding heterogenous variants based on the heterogeneity in dependent instrument (HEIDI) test (Methods, Supplementary Fig. 6, Supplementary Data 10). Consistent with evidence from RCTs and genetic studies⁴², we found evidence for causal effects of higher diastolic blood pressure (DBP; OR = 1.30 per 10 mmHg, $P = 9.13 \times 10^{-21}$) and systolic blood pressure (SBP; OR = 1.18 per 10 mmHg, $P = 4.8 \times 10^{-23}$), and higher risk of CAD (OR = 1.36, $P = 1.67 \times 10^{-70}$) on HF. We note that the effect estimates for variant associations with blood pressure, included as instrumental variables, were adjusted for BMI, which may attenuate the estimated causal effect on HF. We found a s.d. increment of BMI (equivalent to 4.4 kg m⁻² (men) - 5.4 kg m⁻² (women)⁴³) accounted for a 74% higher HF risk ($P = 2.67 \times 10^{-50}$), consistent with previous reports^{44,45}. We identified evidence supporting causal effects of genetic liability to AF (OR of HF per 1 log odds higher AF = 1.19, $P = 1.40 \times 10^{-75}$) and T2D (OR of HF per 1 log odds higher T2D = 1.05, $P = 6.35 \times 10^{-05}$) and risk of HF. We did not find supportive evidence for a causal role for higher heart rate (HR) or lower glomerular filtration rate (GFR) despite reported observational associations^{46,47}. We then performed a sensitivity analysis to explore potential bias arising from the inclusion of case-control samples by repeating the Mendelian randomisation analysis, using HF GWAS estimates generated from population-based cohort studies only. The results of this analysis were consistent with those generated from the overall sample (Supplementary Table 5).

To investigate whether risk factor effects on HF were mediated by CAD and AF, we performed analyses conditioning for CAD and AF using mtCOJO. We observed attenuation of the effect of T2D after conditioning for CAD (OR = 1.02, $P = 0.19$), suggesting at least partial mediation by CAD risk rather than through direct myocardial effects of hyperglycaemia. Similarly, the effects of low-density lipoprotein cholesterol (LDL-C) were fully explained by effects of CAD on HF risk (OR = 1.00, $P = 0.80$).




Fig. 3 Associations of HF risk variants with traits relating to disease subtypes and risk factors. This bubble plot shows associations between the identified HF loci and risk factors and quantitative imaging traits, using summary estimates from UK Biobank (DCM, dilated cardiomyopathy) and published GWAS summary statistics. Number in bracket represents sample size (for quantitative traits) or number of cases (for binary traits) used to derive the GWAS summary statistics. The size of the bubble represents the absolute Z-score for each trait, with the direction oriented towards the HF risk allele. Red/blue indicates a positive/negative cross-trait association (i.e., increase/decrease in disease risk or increase/decrease in continuous trait). We accounted for family-wise error rate at 0.05 by Bonferroni correction for the ten traits tested per HF locus ($P < 4.5e-4$); traits meeting this threshold of significance for association are indicated by dark colour shading. Agglomerative hierarchical clustering of variants was performed using the complete linkage method, based on Euclidian distance. Where a sentinel variant was not available for all traits, a common proxy was selected (bold text). For the LPA locus, associations for the more common of the two variants at this locus are shown. Bold text represents variants whose estimates are plotted, upon which we performed hierarchical agglomerative clustering using the complete linkage method based on Euclidian distance. FS, fractional shortening; LVD, left ventricular dimension; DCM, dilated cardiomyopathy; AF, atrial fibrillation; CAD, coronary artery disease; LDL-C, low-density lipoprotein cholesterol; T2D, type 2 diabetes; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Conversely, the effects of blood pressure, BMI and triglycerides (TGs) were only partially attenuated, suggesting causal mechanisms independent of those associated with AF and CAD (Fig. 4, Supplementary Data 10).

Discussion

We identify 12 independent variant associations for HF risk at 11 genomic loci by leveraging genome-wide data on 47,309 cases and 930,014 controls, including 10 loci not previously associated with HF. The identified loci were associated with modifiable risk factors and traits related to LV structure and function, and include the strongest associations signals from GWAS of CAD (9p21, *LPA*)¹⁸, AF (*PITX2*)¹⁷ and BMI (*FTO*)²⁰. Conditioning for CAD, AF and blood pressure traits demonstrated that the effects of some loci (e.g., 9p21/*CDKN2B-AS1*) were mediated wholly via risk factor trait associations (e.g., CAD); however, for 8 of 12 variants the attenuation of effects was <50%, suggesting alternative mechanisms may be important. Those loci associated with reduced LV systolic function or AF mapped to candidate genes implicated in processes of cardiac development, protein homeostasis and cellular senescence. We use genetic causal inference and conditional analysis to explore the syndromic heterogeneity and causal biology of HF, and to provide insights into aetiology. Mendelian randomisation analysis confirms previously reported casual effects for BMI and provides evidence supporting the causal role of several observationally linked risk factors, including AF, elevated blood pressure (DBP and SBP), LDL-C, CAD, TGs and T2D. Using conditional analysis, we demonstrate CAD-independent effects for AF, BMI, blood pressure and estimate that the effects of T2D are mostly mediated by an increased risk of CAD.

The heterogeneity of aetiology and clinical manifestation of HF are likely to have reduced statistical power. We identify a modest number of genetic associations for HF compared to other cardiovascular disease GWAS of comparable sample size, such as for AF, suggesting that an important component of HF heritability may be more attributable to specific disease subtypes than components of a final common pathway¹⁷. Subsequent studies will explore emerging opportunities to define HF subtypes and longitudinal phenotypes in large biobanks and patient registries at scale using standardised definitions based on diagnostic codes, imaging and electronic health records. We speculate that future analysis of HF subtypes may yield additional insights into the genetic architecture of HF to inform new approaches to prevention and treatment.

Methods

Samples. Participants of European ancestry from 26 cohorts (with a total of 29 distinct datasets) with either a case-control or population-based study design were included in the meta-analysis, as part of the HERMES Consortium. Cases included participants with a clinical diagnosis of HF of any aetiology with no inclusion criteria based on LV ejection fraction; controls were participants without HF. Definitions used to adjudicate HF status within each study are detailed in the Supplementary Data 11 and baseline characteristics for each study are provided in Supplementary Data 12. We meta-analysed data from a total of 47,309 cases and 930,014 controls. All included studies were ethically approved by local institutional review boards and all participants provided written informed consent. The meta-analysis of summary-level GWAS estimates from participating studies was performed in accordance with guidelines for study procedures provided by the UCL Research Ethics Committee.

Genotyping and imputation. All studies used high-density genotyping arrays and performed genotype calling and pre-imputation quality control (QC), as reported in Supplementary Data 13. Studies performed imputation using one or more of the following reference panels: 1000 Genomes (Phase 1 or Phase 3)⁴⁸, Hapmap 2 NCBI build 36⁴⁹, Haplotype Reference Consortium (HRC)⁵⁰, the Estonian Whole-




Fig. 4 Conditional Mendelian randomisation analyses of HF risk factors.

Forest plot of HF risk factors with significant causal effect HF risk estimated using Mendelian randomisation, implemented with GSMR. Diamonds represent the odds ratio and the error bars indicate the 95% confidence interval. The unadjusted estimates represent the risk of HF as estimated from the HF GWAS data, while the adjusted estimates represent risk of HF conditioned, using GWAS summary statistics for atrial fibrillation (adjusted for AF) or coronary artery disease (adjusted for CAD) estimated using the mtCOJO method. For binary traits (coronary artery disease, atrial fibrillation and type 2 diabetes), the MR estimates represent average causal effect per natural-log odds increase in the trait risk. For continuous traits, the MR estimates represent average causal effect per standard deviation increase in the reported unit of the trait. LDL, low-density lipoprotein; HDL, high-density lipoprotein; CAD, coronary artery disease; AF, atrial fibrillation.

Genome Sequence reference⁵¹ or a reference sample based on 15,220 whole-genome sequences of Icelandic individuals. The following software tools were used by studies for phasing: Eagle⁵², MaCH⁵³ and SHAPEIT⁵⁴; and imputation: mimamc2⁵⁵ and IMPUTE2⁵⁶. For imputation to the HRC reference panel, the Sanger Imputation Server (<https://www.sanger.ac.uk/science/tools/sanger-imputation-service>) was used. The deCODE study was imputed using study specific procedures⁵⁷. Methods for phasing, imputation and post-imputation QC for each study are detailed in Supplementary Data 13.

Study-level GWA analysis. GWA analysis for each study was performed locally according to a common analysis plan, and summary-level estimates were provided for meta-analysis. Autosomal single-nucleotide polymorphisms (SNPs) were tested for association with HF using logistic regression, assuming additive genetic effects. For the Cardiovascular Health Study, HF association estimates were generated by analysis of incident cases using a Cox proportional hazards model. All studies included age and sex (except for single-sex studies) as covariates in the regression models. Principal components (PCs) were included as covariates for individual studies as appropriate. The following tools were used for study-level GWA analysis: ProbABEL⁵⁸, mach2dat (<http://www.unc.edu/~yunmli/software.html>), QuickT-test⁵⁹, PLINK2⁶⁰, SNPTEST⁶¹ or R² as detailed in Supplementary Data 13.

QC on study summary-level data. QC of summary-level results for each study was performed according to the protocol described in Winkler et al.⁶³. In brief, we used the EasyQC tool to harmonise variant IDs and alleles across studies and to compare reported allele frequencies with allele frequencies in individuals of European ancestry from the 1000 Genomes imputation reference panel⁶⁴. We inspected P - Z plots (reported P value against Z -score), beta and s.e. distributions, and Manhattan plots to check for consistency and to

identify spurious associations. For each study, variants were removed if they satisfied any one of the following criteria: imputation quality < 0.5 , MAF < 0.01 , absolute betas and s.e. > 10 . As recommended in Sinnott et al.⁶⁵ and Johnson et al.⁶⁶, more stringent QC measures were applied to studies where genotyping of cases and controls was performed on different platforms. This included more stringent thresholds for removing SNPs with low-quality imputation, and where available, individuals genotyped on both platforms were used to remove SNPs with low concordance rates between the two platforms. To check for study-level genomic inflation, we examined quantile–quantile plots and calculated the genomic inflation factor (λ_{GC}). For three studies, where some degree of genomic inflation was observed ($\lambda_{GC} > 1.1$), genomic control correction was applied (Supplementary Data 13)⁶⁷.

Meta-analysis. Meta-analysis of summary data was conducted using the fixed-effect IVW approach implemented in METAL (released March 25 2011)⁶⁸. Variants were included if they were present in at least half of all studies. We tested for inflation of the meta-analysis test statistic due to cryptic population structure by estimating the LDSC intercept, implemented using LDSC v1.0.0¹³. As the LDSC intercept indicated no inflation (LD score intercept of 1.0069), no further correction was applied to the meta-analysis summary estimates. To identify variants independently associated with HF, we analysed the genome-wide results using FUMA v1.3.2⁶⁹, selecting a random sample of 10,000 UK Biobank participants of European ancestry as an LD reference dataset⁷⁰. Variants were filtered using a $P < 5 \times 10^{-8}$ and independent genomic loci were LD-pruned based on an $r^2 < 0.1$. We calculated Cochran's Q and I^2 statistics to assess whether the effect estimates for HF sentinel variants were consistent across studies⁷¹.

Heritability estimation. To estimate the proportion of HF risk explained by common variants we estimated heritability h_g^2 on the liability scale, using LDSC on the UK Biobank summary data (6,504 HF cases, 387,652 controls), assuming a population prevalence of 2.5%¹⁴. This approach assumes that a binary trait has an underlying continuous liability, and above a certain liability threshold an individual becomes affected. We can then estimate the genetic contribution to the continuous liability. Sample ascertainment can change the distribution of liability in the sampled individuals and needs to be adjusted for, which requires making assumptions about the population prevalence of the trait.

LD reference dataset. A LD reference was created, including 10,000 UK Biobank participants of European ancestry, based on HRC-imputed genotypes (referred to henceforth as UKB10K). European individuals were identified by projecting the UK Biobank samples onto the 1000 G Phase 3 samples. A genomic relationship matrix was constructed using HapMap3 variants, filtered for MAF > 0.01 , $P_{HWE} < 10^{-6}$ and missingness < 0.05 in the European subset, and one member of each pair of samples with observed genomic relatedness > 0.05 was excluded to obtain a set of unrelated European individuals. Random sampling without replacement was used to extract a subset of 10,000 unrelated individuals of European ancestry. Variants with a minor allele count > 5 , a genotype probability > 0.9 and imputation quality > 0.3 were converted to hard calls. This LD reference dataset was used for downstream summary-based analysis and for identifying SNP proxies.

Gene set enrichment analysis. A gene-based and gene set enrichment analysis of variant associations was performed using MAGMA²⁶, implemented by FUMA v1.3.2⁶⁹. This analysis was performed using summary-level meta-analysis results. First, a gene-based association analysis to identify candidate genes associated with HF was conducted. Second, a tissue enrichment analysis of HF-associated genes was performed using gene expression data for 30 tissues from GTEx. Finally, a gene set enrichment analysis was performed based on pathway annotations from the Gene Ontology database⁷². For all MAGMA analyses, multiple testing was accounted for by Bonferroni correction.

Missense consequences of sentinel variants and proxies. We queried the protein coding consequence of the sentinel variants and proxies ($r^2 > 0.8$) using the Combined Annotation Dependent Depletion (CADD) score⁷³, implemented using FUMA v1.3.2⁶⁹. The CADD score integrates information from 63 distinct functional annotations into a single quantitative score, ranging from 1 to 99, based on variant rank relative to all 8.6 billion possible single nucleotide variants of the human reference genome (GRCh37). Sentinel SNPs or proxies with CADD score > 20 were identified. A CADD score of 20 indicates that the variant is ranked in the top 1% of highest scoring variants, while a CADD score of 30 indicates the variant is ranked in the top 0.1%.

Expression quantitative trait analysis. To determine if HF sentinel variants had *cis* effects on gene expression, we queried two eQTL datasets based on RNA sequencing of human heart tissue—the GTEx v7 resource⁷⁴ and the MAGNet repository (<http://www.med.upenn.edu/magnet/>). The GTExv7 sample included 272 LV and 264 RAA non-diseased tissue samples from European (83.7%) and African Americans (15.1%) individuals. The MAGNet repository included 89 LV and 101 LA tissue samples obtained from rejected donor tissue from hearts with no

evidence of structural disease; and 89 LV samples from individuals with DCM, obtained at the time of transplantation. eQTL analysis of the LV data from MAGNet analysis was performed using the QTLtools package⁷⁵ in DCM with adjustment for age, sex, disease status and the first three genetic PCs. To account for observed batch effects, a surrogate variant analysis was performed using the R package SVaseq⁷⁶ and 22 additional covariates were identified and included in the model. Existing eQTL summary data in LA tissue from MAGNet and heart tissue from GTEX were queried^{17,77}. We queried HF sentinel variants for eQTL associations with genes located either fully or partly within a 1 megabase (Mb) region upstream or downstream of the sentinel variant (referred to as *cis*-genes). We accounted for multiple testing by adjusting a significance threshold of $P < 0.05$ for the total number of SNP-*cis*-gene tests performed across the four heart tissue eQTL datasets ($P < 4.73E-05$ for a total of 1,056 SNP-gene associations). Baseline characteristics for the MAGNet study are provided in Supplementary Table 6. We also queried sentinel HF variants for associations with *cis* gene expression in blood from the eQTLGen consortium ($N = 31,684$)²⁹. Given the large sample size, we used a stringent genome-wide significance threshold of $P < 5 \times 10^{-8}$ to identify significant blood eQTLs.

Colocalisation analysis. Bayesian colocalisation analysis was performed using R package *coloc* to test whether shared associations with gene expression and HF risk were consistent with a single common causal variant hypothesis³⁰. We tested all genes with significant *cis*-eQTL association by analysing all variants within a 200 kilobase window around the gene using eQTL summary data for heart tissues and whole blood, and HF summary data from present study. We set the prior probability of a SNP being associated only with gene expression, only with HF, or with both traits as 10^{-4} , 10^{-4} and 10^{-5} . For each gene, we report the posterior probability that the association with gene expression and HF risk is driven by a single causal variant. We consider a posterior probability of ≥ 0.7 as providing evidence, supporting a causal role for the gene as a mediator of HF risk.

Transcriptome-wide association analysis. We employed the S-PrediXcan method⁷⁸ implemented in the MetaXcan software (<https://github.com/hakymimlab/MetaXcan>) to identify genes whose predicted expression levels in heart tissue are associated with HF risk. Prediction models trained on GTEXv7 heart tissue datasets were applied to the HERMES meta-analysis results. Only models that significantly predicted gene expression in the GTEX eQTL dataset (false discovery rate < 0.05) were considered. A total of 4859 genes were tested in left ventricle tissue and 4467 genes for right atrial appendage. Genes with an association $P < 5.36 \times 10^{-6}$ [0.05/(4859 + 4467)] were considered to have gene expression profiles significantly associated with HF.

Protein quantitative trait analysis in blood. We queried both *cis*- and *trans*-protein QTL (pQTL) associations based on measures for serum proteins mapping to 3000 genes in 3301 healthy individuals from the INTERVAL study³¹. We accounted for multiple testing by adjusting a significance threshold of $P < 0.05$ for the total number of tests for all variants and proteins tested (36,000 tests).

Association of HR risk loci with other phenotypes. We queried associations (with $P < 1 \times 10^{-5}$) of sentinel variants and proxies ($r^2 > 0.6$) with any trait in the NHGRI-EBI Catalog of published GWAS (accessed 21 January 2019)^{15,79}. We report associations (where $P < 1 \times 10^{-5}$) for the sentinel variants with traits in the UK Biobank cohort using the MRBase PheWAS database (<http://phewas.mrbase.org/>, accessed 17 January 2019). The database contains GWA summary data for 4203 phenotypes measured in 361,194 unrelated individuals of European ancestry from the UK Biobank data. We queried GWAS data for ten traits related to HF risk factors, endophenotypes and related disease traits using summary-level data from the largest available GWAS study (either publicly available or through agreement with study investigators). The following phenotypes were considered: fractional shortening (FS), LV dimension¹⁶, DCM; AF¹⁷, CAD¹⁸, LDL-C²², T2D²³; BMI²⁰, SBP and DBP¹⁹. For DCM, a GWAS was performed in the UKB among individuals of European ancestry with cases defined by the presence of ICD10 code I42.0 as a main/secondary diagnosis or primary/secondary cause of death with non-cases as referents, using PLINK2. Logistic regression was performed with adjustment for age, sex, genotyping array and the first ten PCs.

Hierarchical agglomerative clustering. We performed hierarchical agglomerative clustering on a locus level using the complete linkage method based on the associations with related traits as described above. Where a sentinel variant is not available in any of the other traits summary results, a common proxy is used in place of the sentinel variant. For the *LPA* locus, we used associations for a proxy of the more common variant (rs55730499). Dissimilarity structure was calculated using Euclidean distance based on the Z-score (beta of continuous traits or log odds of disease risk divided by s.e.) of the cross-trait associations. We accounted for multiple testing at family-wise error rate of 0.05 by Bonferroni correction for the ten traits tested per HF locus (110 tests), and considered $P < 4.5E^{-4}$ (0.05/110) as our significance threshold for association.

Genetic correlation analysis. We estimated genetic correlation between HF and 11 risk factors using LDSC¹³ on the GWAS summary statistics for each trait: AF¹⁷, CAD¹⁸, LDL-C, high-density lipoprotein cholesterol (HDL-C), TGs²², T2D²³; BMI²⁰, SBP, DBP¹⁹, HR²¹ and estimated GFR⁸⁰.

Mendelian randomisation analysis. We performed two sample Mendelian randomisation analysis using the Generalised summary data-based Mendelian randomisation (GSMR)²⁵ implemented in GCTA v1.91.7beta⁸¹. To identify independent SNP instruments for each exposure, GWAS-significant SNPs ($P < 5 \times 10^{-8}$) for each risk factor were pruned ($r^2 < 0.05$; LD window of 10,000 kb; using the UKB10K LD reference). We then estimated the causal effect of the risk factor on the disease trait according to the MR paradigm. The HEIDI test implemented in GSMR was used to detect and remove (if HEIDI $P < 0.01$) variants showing horizontal pleiotropy i.e., having independent effects on both exposure and outcome, as such variants do not satisfy the underlying assumptions for valid instruments. As sensitivity analyses, we estimated the causal effects of known risk factors on HF risk other statistical methodology and software—the R package TwoSampleMR⁸² was used to select independent variant instruments for the exposure using the same parameters as per the GSMR analysis ($P < 5 \times 10^{-8}$; $r^2 < 0.05$; LD window of 10,000 kb), except the TwoSampleMR package uses the 1000 Genomes as the LD reference. Causal estimates based on the IVW⁸³, MR-Egger and median-weighted methods⁸⁴ were then calculated using the Mendelian Randomisation⁸⁵ R package. To enable comparison of MR estimates between traits, we present effect estimates corresponding to the risk of HF for a 1-s.d. higher risk factor of interest. Where the original GWAS conducted rank-based inverse normal transformation (RINT) of a trait prior to GWAS, we used the per-allele beta coefficients following RINT to approximate the equivalent values on the standardised scale, as has been conducted previously.

To determine if the causal effects of the continuous risk factors on HF were mediated via their effects on CAD or AF risk, we repeated the GSMR analysis after conditioning the HF summary statistics on CAD and AF GWAS summary statistics, as described below.

Conditional analysis. To estimate the effects of HF risk variants after adjusting for risk factors which showed a significant causal effect on HF in the MR analyses, we performed the mtCOJO on summary data, as implemented in GCTA v1.91.7beta⁸¹. HF summary statistics were adjusted for AF¹⁷, CAD¹⁸, LDL-C, HDL-C, TGs²², DBP, SBP¹⁹ and BMI²⁰ using GWAS summary data. The UKB10K LD reference was used.

Reporting summary. Further information is provided in the Nature Research Reporting Summary.

Data availability

The datasets generated during this study are available from the corresponding author upon reasonable request. The summary GWAS estimates for this analysis are available on the Cardiovascular Disease Knowledge Portal (<http://www.broadcvdi.org/>).

Received: 8 July 2019; Accepted: 18 November 2019;

Published online: 09 January 2020

References

- Ziaeeian, B. & Fonarow, G. C. Epidemiology and aetiology of heart failure. *Nat. Rev. Cardiol.* **13**, 368–378 (2016).
- Roger, V. L. et al. Trends in heart failure incidence and survival in a community-based population. *JAMA* **292**, 344 (2004).
- Ponikowski, P. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur. Heart J.* **37**, 2129–2200 (2016).
- Kenchaiah, S. et al. Obesity and the risk of heart failure. *N. Engl. J. Med.* **347**, 305–313 (2002).
- Cahill, T. J., Ashrafian, H. & Watkins, H. Genetic cardiomyopathies causing heart failure. *Circ. Res.* **113**, 660–675 (2013).
- Lindgren, M. P. et al. A Swedish Nationwide Adoption Study of the heritability of heart failure. *JAMA Cardiol.* **3**, 703–710 (2018).
- Aragam, K. G. et al. Phenotypic refinement of heart failure in a National Biobank facilitates genetic discovery. *Circulation* **139**, 489–501 (2019).
- Smith, N. L. et al. Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. *Circ. Cardiovasc. Genet.* **3**, 256–266 (2010).
- Meder, B. et al. A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. *Eur. Heart J.* **35**, 1069–1077 (2014).
- Esslinger, U. et al. Exome-wide association study reveals novel susceptibility genes to sporadic dilated cardiomyopathy. *PLoS One.* **12**, e0172995 (2017).

11. Villard, E. et al. A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. *Eur. Heart J.* **32**, 1065–1076 (2011).
12. Davey Smith, G. & Ebrahim, S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *Int. J. Epidemiol.* **32**, 1–22 (2003).
13. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
14. Benjamin, E. J. et al. Heart Disease and Stroke Statistics—2018 update: a report from the American Heart Association. *Circulation* **137**, e67–e492 (2018).
15. Welter, D. et al. The NHGRI GWAS catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res.* **42**, D1001–D1006 (2014).
16. Wild, P. S. et al. Large-scale genome-wide analysis identifies genetic variants associated with cardiac structure and function. *J. Clin. Invest.* **127**, 1798–1812 (2017).
17. Roselli, C. et al. Multi-ethnic genome-wide association study for atrial fibrillation. *Nat. Genet.* **50**, 1225–1233 (2018).
18. Nikpay, M. et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat. Genet.* **47**, 1121–1130 (2015).
19. Warren, H. R. et al. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. *Nat. Genet.* **49**, 403–415 (2017).
20. Locke, A. E. et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature* **518**, 197–206 (2015).
21. Eppinga, R. N. et al. Identification of genomic loci associated with resting heart rate and shared genetic predictors with all-cause mortality. *Nat. Genet.* **48**, 1557–1563 (2016).
22. Willer, C. J. et al. Discovery and refinement of loci associated with lipid levels. *Nat. Genet.* **45**, 1274–1283 (2013).
23. Scott, R. A. et al. An expanded genome-wide association study of type 2 diabetes in Europeans. *Diabetes* **66**, 2888–2902 (2017).
24. Santhanakrishnan, R. et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. *Circulation* **133**, 484–492 (2016).
25. Zhu, Z. et al. Causal associations between risk factors and common diseases inferred from GWAS summary data. *Nat. Commun.* **9**, 1–12 (2018).
26. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput. Biol.* **11**, e1004219 (2015).
27. Domínguez, F. et al. Dilated cardiomyopathy due to BLC2-associated athanogene 3 (BAG3) mutations. *J. Am. Coll. Cardiol.* **72**, 2471–2481 (2018).
28. Zeng, L. et al. Cis-epistasis at the LPA locus and risk of coronary artery disease. Preprint at <https://doi.org/10.1101/518290> (2019).
29. Vösa, U. et al. Unraveling the polygenic architecture of complex traits using blood eQTL metaanalysis. Preprint at <https://doi.org/10.1101/447367> (2018).
30. Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet.* **10**, e1004383 (2014).
31. Sun, B. B. et al. Genomic atlas of the human plasma proteome. *Nature* **558**, 73–79 (2018).
32. Frey, N. et al. Calcineurin-2 deficiency increases exercise capacity in mice through calcineurin/NFAT activation. *J. Clin. Invest.* **118**, 3598–3608 (2008).
33. Molkenin, J. D. Parsing good versus bad signaling pathways in the heart: role of calcineurin-nuclear factor of activated T-cells. *Circ. Res.* **113**, 16–19 (2013).
34. Beqqali, A. et al. CHAP is a newly identified Z-disc protein essential for heart and skeletal muscle function. *J. Cell. Sci.* **123**, 1141–1150 (2010).
35. Behl, C. Breaking BAG: the co-chaperone BAG3 in health and disease. *Trends Pharmacol. Sci.* **37**, 672–688 (2016).
36. Tane, S. et al. CDK inhibitors, p21Cip1 and p27Kip1, participate in cell cycle exit of mammalian cardiomyocytes. *Biochem. Biophys. Res. Commun.* **443**, 1105–1109 (2014).
37. Mattioli, E. et al. Altered modulation of lamin A/C-HDAC2 interaction and p21 expression during oxidative stress response in HGPS. *Aging Cell* **17**, e12824 (2018).
38. Boyden, L. M. et al. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. *Nature* **482**, 98–102 (2012).
39. Sciarretta, S., Palano, F., Tocci, G., Baldini, R. & Volpe, M. Antihypertensive treatment and development of heart failure in hypertension. *Arch. Intern. Med.* **171**, 384–394 (2011).
40. Velagaleti, R. S. & Vasan, R. S. Heart failure in the twenty-first century: is it a coronary artery disease or hypertension problem? *Cardiol. Clin.* **25**, 487–495 (2007). v.
41. Roger, V. L. Epidemiology of heart failure. *Circ. Res.* **113**, 646–659 (2013).
42. Ntalla, I. et al. Genetic risk score for coronary disease identifies predispositions to cardiovascular and noncardiovascular diseases. *J. Am. Coll. Cardiol.* **73**, 2932–2942 (2019).
43. Fry, A. et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. *Am. J. Epidemiol.* **186**, 1026–1034 (2017).
44. He, L. et al. Causal effects of cardiovascular risk factors on onset of major age-related diseases: a time-to-event Mendelian randomization study. *Exp. Gerontol.* **107**, 74–86 (2018).
45. Fall, T. et al. The role of adiposity in cardiometabolic traits: a Mendelian randomization analysis. *PLoS Med.* **10**, e1001474 (2013).
46. Dhingra, R., Gaziano, J. M. & Djoussé, L. Chronic kidney disease and the risk of heart failure in men. *Circ. Heart Fail.* **4**, 138–144 (2011).
47. Nanchen, D. et al. Resting heart rate and the risk of heart failure in healthy adults. *Circ. Heart Fail.* **6**, 403–410 (2013).
48. The 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. *Nature* **467**, 1061–1073 (2010).
49. International HapMap, Consortium et al. A second generation human haplotype map of over 3.1 million SNPs. *Nature* **449**, 851–861 (2007).
50. the Haplotype Reference Consortium et al. A reference panel of 64,976 haplotypes for genotype imputation. *Nat. Genet.* **48**, 1279–1283 (2016).
51. Miit, M. et al. Improved imputation accuracy of rare and low-frequency variants using population-specific high-coverage WGS-based imputation reference panel. *Eur. J. Hum. Genet.* **25**, 869–876 (2017).
52. Loh, P.-R., Palamara, P. F. & Price, A. L. Fast and accurate long-range phasing in a UK Biobank cohort. *Nat. Genet.* **48**, 811–816 (2016).
53. Li, Y., Willer, C. J., Ding, J., Scheet, P. & Abecasis, G. R. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. *Genet. Epidemiol.* **34**, 816–834 (2010).
54. Delaneau, O., Zagury, J.-F. & Marchini, J. Improved whole-chromosome phasing for disease and population genetic studies. *Nat. Methods* **10**, 5–6 (2013).
55. Fuchsberger, C., Abecasis, G. R. & Hinds, D. A. minimac2: faster genotype imputation. *Bioinformatics* **31**, 782–784 (2015).
56. Howie, B. N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet.* **5**, e1000529 (2009).
57. Kong, A. et al. Detection of sharing by descent, long-range phasing and haplotype imputation. *Nat. Genet.* **40**, 1068–1075 (2008).
58. Aulchenko, Y. S., Struchalin, M. V. & van Duijn, C. M. ProbABEL package for genome-wide association analysis of imputed data. *BMC Bioinforma.* **11**, 134 (2010).
59. Kutalik, Z. et al. Methods for testing association between uncertain genotypes and quantitative traits. *Biostatistics* **12**, 1–17 (2011).
60. Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, 7 (2015).
61. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. *Nat. Genet.* **39**, 906–913 (2007).
62. R Core team. R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria <http://www.R-project.org/> (2015).
63. Winkler, T. W. et al. Quality control and conduct of genome-wide association meta-analyses. *Nat. Protoc.* **9**, 1192–1212 (2014).
64. The 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).
65. Sinnott, J. A. & Kraft, P. Artifact due to differential error when cases and controls are imputed from different platforms. *Hum. Genet.* **131**, 111–119 (2012).
66. Johnson, E. O. et al. Imputation across genotyping arrays for genome-wide association studies: assessment of bias and a correction strategy. *Hum. Genet.* **132**, 509–522 (2013).
67. Devlin, B. & Roeder, K. Genomic control for association studies. *Biometrics* **55**, 997–1004 (1999).
68. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
69. Watanabe, K., Taskesen, E., Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1–11 (2017).
70. Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018).
71. Higgins, J. P. T., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. *BMJ* **327**, 557–560 (2003).
72. Ashburner, M. et al. Gene Ontology: tool for the unification of biology. *Nat. Genet.* **25**, 25–29 (2000).
73. Kircher, M. et al. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat. Genet.* **46**, 310–315 (2014).
74. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* **45**, 580–585 (2013).
75. Delaneau, O. et al. A complete tool set for molecular QTL discovery and analysis. *Nat. Commun.* **8**, 15452 (2017).

76. Leek, J. T. Osvaseq: removing batch effects and other unwanted noise from sequencing data. *Nucleic Acids Res.* **42**, (2014).
77. GTEx Consortium et al. Genetic effects on gene expression across human tissues. *Nature* **550**, 204–213 (2017).
78. Barbeira, A. N. et al. Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. *Nat. Commun.* **9**, 1825 (2018).
79. MacArthur, J. et al. The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). *Nucleic Acids Res.* **45**, D896–D901 (2017).
80. Gorski, M. et al. 1000 Genomes-based meta-analysis identifies 10 novel loci for kidney function. *Sci. Rep.* **7**, 45040 (2017).
81. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. *Am. J. Hum. Genet.* **88**, 76–82 (2011).
82. Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenotype. *eLife* **7**, e34408 (2018).
83. Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet. Epidemiol.* **37**, 658–665 (2013).
84. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int. J. Epidemiol.* **44**, 512–525 (2015).
85. Yavorska, O. O. & Burgess, S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. *Int. J. Epidemiol.* **46**, 1734–1739 (2017).

Acknowledgements

We acknowledge the contribution from the EchoGen Consortium. A full list of contributing authors and further acknowledgements are given in Supplementary Notes 4 and 5.

Author contributions

S. Shah, J.B.W., F.A., A.D.H., C.C.L., J.G.S., R.S.V., D.I.S. and R.T.L. are members of HERMES executive committee. S. Shah, A. Henry, H. Holm, M.V.H., F.A., A.D.H., K. Kuchenbaecker, P.T.E., C.C.L., J.G.S., R.S.V., D.I.S. and R.T.L. drafted and finalised the manuscript. S. Shah, A. Henry, C.R., H.L., G.S., Å.K.H., M.D.C., A. Helgadottir, C.A., W.C., S.D., D.F.G., P.v.d.H., E.I., R.C.L., T.M., C.P.N., T.N., B.M.P., K.M.R., S.P.R.R., J.v.S., N.L.S., P. Svensson, K.D.T., G.T., B.T., A.A.V., X.W., H.X., H. Hemingway, N.J.S., J.J.M., J.Y., P.M.V., A. Malarstig, H. Holm, S.A.L., N.S., M.V.H., T.P.C., F.A., A.D.H., K. Kuchenbaecker, P.T.E., C.C.L., J.G.S., R.S.V., D.I.S. and R.T.L. contributed to and revised the manuscript. C.R., H.L., G.S., G.F., Å.K.H., J.B.W., M.P.M., M.D.C., A. Helgadottir, N.V., A.D., P.A., C.A., K.G.A., J.Ä., J.D.B., M.L.B., H.L.B., J.B., Broad AF Investigators, M.R.B., L.B., D.J.C., R.G.C., D.I.C., Xing Chen, Xu Chen, J.C., J.P.C., G.E.D., S.D., A.S.D., M.D., S.C.D., M.E.D., EchoGen Consortium, G.E., T.E., S.B.F., C.F., I.F., M.G., S. Ghasemi, V.G., F.G., J.S.G., S. Gross, D.F.G., R.G., C.M.H., P.v.d.H., C.L.H., E.I., J.W.J., M.K., K. Khaw, M.E.K., L.K., A.K., C.L., L.L., C.M.L., B.L., L.A.L., J.L., P.M., A. Mahajan, K.B.M., W.M., O.M., I.R.M., A.D.M., A.P.M., A.C.M., M.W.N., C.P.N., A.N., T.N., M.L.O., A.T.O., C.N.A.P., H.M.P., M.P., E.P., B.M.P., K.M.R., P.M.R., S.P.R.R., J.I.R., P. Salo, V.S., A.A.S., D.T.S., N.L.S., S. Stender, D.J.S., P. Svensson, M. Tammesoo, K.D.T., M. Teder-Laving, A.T., G.T., U.T., C.T., S.T., A.G.U., A.V., U.V., A.A.V., N.J.W., D.W., P.E.W., R.W., K.L.W., L.M.Y., B.Y., F.Z., J.H.Z., N.J.S., C.N., A. Malarstig, H. Holm, S.A.L., N.S., T.P.C., K. Kuchenbaecker, P.T.E., C.C.L., K.S., J.G.S., R.S.V., D.I.S. and R.T.L. contributed to study-specific GWAS by providing phenotype data or performing data analyses. S. Shah and H.L. performed meta-analyses. C.R., M.P.M., J.B., K.B.M. and T.P.C. provided heart eQTL data, and contributed to analysis. S. Shah, A. Henry, C.R., G.F., M.V.H. and R.T.L. performed downstream analyses. S. Shah, F.A., A.D.H., K. Kuchenbaecker, P.T.E., C.C.L., J.G.S., R.S.V., D.I.S. and R.T.L. conceived, designed, and supervised the overall project. Contribution statements from Regeneron Genetics Center are provided in Supplementary Note 6. All authors have approved the final version of the manuscript.

Competing interests

J.B.W., L.B., Xing Chen, C.L.H., M.W.N. and A. Malarstig are current or former employee of Pfizer who may hold Pfizer stock and/or stock options. J.D.B. and J.C. are employees of Regeneron Genetics Center. M.E.D. is an employee of Regeneron Pharmaceuticals. W.M. reports grants and personal fees from Siemens Diagnostics, grants and personal fees from Aegerion Pharmaceuticals, grants and personal fees from AMGEN, grants and personal fees from Astrazeneca, grants and personal fees from Danone Research, personal fees from Hoffmann LaRoche, personal fees from MSD, grants and personal fees from Pfizer, personal fees from Sanofi, personal fees from Synageva, grants and personal fees from BASF, grants from Abbott Diagnostics, grants and personal fees from Numares AG, grants and personal fees from Berlin-Chemie, employment with Synlab Holding Deutschland GmbH, all outside the submitted work. M.L.O. reports grant support from GlaxoSmithKline, Eisai, Janssen, Merck and AstraZeneca. B.M.P. serves on the DSMB of a clinical trial funded by Zoll LifeCor and on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. V.S. participated in a conference trip sponsored by Novo Nordisk and received a honorarium from the same source for participating in an advisory board meeting. He also has ongoing research collaboration with Bayer Ltd. B.T. is a full-time employee of Servier. S.A.L. receives sponsored research support from Bristol Myers Squibb/Pfizer, Bayer AG and Boehringer Ingelheim, and has consulted for Abbott, Quest Diagnostics and Bristol Myers Squibb/Pfizer. M.V.H. has collaborated with Boehringer Ingelheim in research, and in accordance with the policy of the The Clinical Trial Service Unit and Epidemiological Studies Unit (University of Oxford), did not accept any personal payment. P.T.E. receives sponsored research support from Bayer AG, and has consulted with Bayer AG, Novartis and Quest Diagnostics. D.I.S. is a full-time employee of BenevolentAI. R.T.L. has received research grants from Pfizer. The remaining authors declare no competing interest.

Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41467-019-13690-5>.

Correspondence and requests for materials should be addressed to R.T.L.

Peer review information *Nature Communications* thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020

Sonia Shah ^{1,2,3,11,2}, Albert Henry ^{2,3,4,11,2}, Carolina Roselli ^{5,6}, Honghuang Lin ^{7,8}, Garðar Sveinbjörnsson ⁹, Ghazaleh Fatemifar ^{3,4,10}, Åsa K. Hedman ¹¹, Jemma B. Wilk ¹², Michael P. Morley ¹³, Mark D. Chaffin ⁵, Anna Helgadottir ⁹, Niek Verweij ^{5,6}, Abbas Dehghan ^{14,15}, Peter Almgren ¹⁶, Charlotte Andersson ^{8,17}, Krishna G. Aragam ^{5,18,19}, Johan Ärnlöv ^{20,21}, Joshua D. Backman ²², Mary L. Biggs ^{23,24}, Heather L. Bloom ²⁵, Jeffrey Brandimarto ¹³, Michael R. Brown ²⁶, Leonard Buckbinder ¹², David J. Carey ²⁷, Daniel I. Chasman ^{28,29}, Xing Chen ¹², Xu Chen ³⁰, Jonathan Chung ²², William Chutkow ³¹, James P. Cook ³², Graciela E. Delgado ³³, Spiros Denaxas ^{3,4,10,34,35}, Alexander S. Doney ³⁶, Marcus Dörr ^{37,38}, Samuel C. Dudley ³⁹, Michael E. Dunn ⁴⁰, Gunnar Engström ¹⁶, Tõnu Esko ^{5,41}, Stephan B. Felix ^{37,38}, Chris Finan ^{2,3}, Ian Ford ⁴², Mohsen Ghanbari ⁴³,

Sahar Ghasemi^{38,44}, Vilmantas Giedraitis⁴⁵, Franco Giulianini²⁸, John S. Gottdiener⁴⁶, Stefan Gross^{37,38}, Daniël F. Guðbjartsson^{9,47}, Rebecca Gutmann⁴⁸, Christopher M. Haggerty²⁷, Pim van der Harst^{6,49,50}, Craig L. Hyde¹², Erik Ingelsson^{51,52,53,54}, J. Wouter Jukema^{55,56}, Maryam Kavousi⁴³, Kay-Tee Khaw⁵⁷, Marcus E. Kleber³³, Lars Køber⁵⁸, Andrea Koekemoer⁵⁹, Claudia Langenberg⁶⁰, Lars Lind⁶¹, Cecilia M. Lindgren^{5,62,63}, Barry London⁶⁴, Luca A. Lotta⁶⁰, Ruth C. Lovering^{2,3}, Jian'an Luan⁶⁰, Patrik Magnusson³⁰, Anubha Mahajan⁶³, Kenneth B. Margulies¹³, Winfried März^{32,65,66}, Olle Melander⁶⁷, Ify R. Mordi³⁶, Thomas Morgan^{31,68}, Andrew D. Morris⁶⁹, Andrew P. Morris^{32,63}, Alanna C. Morrison²⁶, Michael W. Nagle¹², Christopher P. Nelson⁵⁹, Alexander Niessner⁷⁰, Teemu Niiranen^{71,72}, Michelle L. O'Donoghue⁷³, Anjali T. Owens¹³, Colin N.A. Palmer³⁶, Helen M. Parry³⁶, Markus Perola⁷¹, Eliana Portilla-Fernandez^{43,74}, Bruce M. Psaty^{75,76}, Regeneron Genetics Center, Kenneth M. Rice²³, Paul M. Ridker^{28,29}, Simon P.R. Romaine⁵⁹, Jerome I. Rotter⁷⁷, Perttu Salo⁷¹, Veikko Salomaa⁷¹, Jessica van Setten⁷⁸, Alaa A. Shalaby⁷⁹, Diane T. Smelser²⁷, Nicholas L. Smith^{76,80,81}, Steen Stender⁸², David J. Stott⁸³, Per Svensson^{84,85}, Mari-Liis Tammesoo⁴¹, Kent D. Taylor⁸⁶, Maris Teder-Laving⁴¹, Alexander Teumer^{38,44}, Guðmundur Thorgeirsson^{9,87}, Unnur Thorsteinsdottir^{9,88}, Christian Torp-Pedersen^{89,90,91}, Stella Trompet^{55,92}, Benoit Tyl⁹³, Andre G. Uitterlinden^{43,94}, Abirami Veluchamy³⁶, Uwe Völker^{38,95}, Adriaan A. Voors⁷, Xiaosong Wang³¹, Nicholas J. Wareham⁶⁰, Dawn Waterworth⁹⁶, Peter E. Weeke⁵⁸, Raul Weiss⁹⁷, Kerri L. Wiggins²⁴, Heming Xing³¹, Laura M. Yerges-Armstrong⁹⁶, Bing Yu²⁶, Faiez Zannad⁹⁸, Jing Hua Zhao⁶⁰, Harry Hemingway^{3,4,10,99}, Nilesh J. Samani⁵⁹, John J.V. McMurray⁹⁹, Jian Yang^{1,100}, Peter M. Visscher^{1,100}, Christopher Newton-Cheh^{5,19,101}, Anders Malarstig^{11,12}, Hilma Holm⁹, Steven A. Lubitz^{5,102}, Naveed Sattar⁹⁹, Michael V. Holmes^{103,104,105}, Thomas P. Cappola¹³, Folkert W. Asselbergs^{2,3,78}, Aroon D. Hingorani^{2,3}, Karoline Kuchenbaecker^{106,107}, Patrick T. Ellinor^{5,102}, Chim C. Lang³⁶, Kari Stefansson^{9,88}, J. Gustav Smith^{5,108,109}, Ramachandran S. Vasan^{8,110}, Daniel I. Swerdlow² & R. Thomas Lumbers^{3,4,10,111*}

¹Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia. ²Institute of Cardiovascular Science, University College London, London, UK. ³British Heart Foundation Research Accelerator, University College London, London, UK. ⁴Institute of Health Informatics, University College London, London, UK. ⁵Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA, USA. ⁶Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. ⁷Section of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, Boston, MA, USA. ⁸National Heart, Lung, and Blood Institute's and Boston University's Framingham Heart Study, Framingham, MA, USA. ⁹deCODE genetics/Amgen Inc., Sturlugata 8, 101, Reykjavik, Iceland. ¹⁰Health Data Research UK London, University College London, London, UK. ¹¹Cardiovascular Medicine unit, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden. ¹²Pfizer Worldwide Research & Development, 1 Portland St, Cambridge, MA, USA. ¹³Penn Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ¹⁴Department of Epidemiology and Biostatistics, Imperial College London, St Mary's Campus, London W2 1PG, UK. ¹⁵MRC-PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics, Imperial College London, St Mary's Campus, London W2 1PG, UK. ¹⁶Department of Clinical Sciences, Lund University, Malmö, Sweden. ¹⁷Department of Cardiology, Herlev Gentofte Hospital, Herlev Ringvej 57, 2650 Herlev, Denmark. ¹⁸Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA. ¹⁹Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA. ²⁰Department of Neurobiology, Care Sciences and Society/ Section of Family Medicine and Primary Care, Karolinska Institutet, Stockholm, Sweden. ²¹School of Health and Social Sciences, Dalarna University, Falun, Sweden. ²²Regeneron Genetics Center, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA. ²³Department of Biostatistics, University of Washington, Seattle, WA, USA. ²⁴Department of Medicine, University of Washington, Seattle, WA, USA. ²⁵Division of Cardiology, Department of Medicine, Emory University Medical Center, Atlanta, GA, USA. ²⁶Department of Epidemiology, Human Genetics, and Environmental Sciences, The University of Texas School of Public Health, Houston, Texas, USA. ²⁷Department of Molecular and Functional Genomics, Geisinger, Danville, PA, USA. ²⁸Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA. ²⁹Harvard Medical School, Boston, MA 02115, USA. ³⁰Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ³¹Novartis Institutes for Biomedical Research, Cambridge, MA, USA. ³²Department of Biostatistics, University of Liverpool, Liverpool, UK. ³³Vth Department of Medicine (Nephrology, Hypertensiology, Endocrinology, Diabetology, Rheumatology), Medical Faculty of Mannheim, University of Heidelberg, Heidelberg, Germany. ³⁴The National Institute for Health Research University College London Hospitals Biomedical Research Centre, University College London, London, UK. ³⁵The Alan Turing Institute, London, United Kingdom. ³⁶Division of Molecular & Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK. ³⁷Department of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany. ³⁸DZHK (German Center for Cardiovascular Research), partner site Greifswald, Greifswald, Germany. ³⁹Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, MN, USA. ⁴⁰Regeneron Pharmaceuticals, Cardiovascular Research, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA. ⁴¹Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu 51010, Estonia. ⁴²Robertson Center for Biostatistics, University of Glasgow, Glasgow, UK.

⁴³Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands. ⁴⁴Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany. ⁴⁵Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, Uppsala 75185, Sweden. ⁴⁶Department of Medicine, Division of Cardiology, University of Maryland School of Medicine, Baltimore, MD, USA. ⁴⁷School of Engineering and Natural Sciences, University of Iceland, 101 Reykjavik, Iceland. ⁴⁸Division of Cardiovascular Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA. ⁴⁹Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. ⁵⁰Durrer Center for Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht, The Netherlands. ⁵¹Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. ⁵²Stanford Cardiovascular Institute, Stanford University, Stanford, CA 94305, USA. ⁵³Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden. ⁵⁴Stanford Diabetes Research Center, Stanford University, Stanford, CA 94305, USA. ⁵⁵Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. ⁵⁶Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands. ⁵⁷Department of Public Health and Primary Care, University of Cambridge, Cambridge CB2 0QQ, UK. ⁵⁸Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. ⁵⁹Department of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK. ⁶⁰MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge CB2 0QQ, UK. ⁶¹Department of Medical Sciences, Uppsala University, Uppsala, Sweden. ⁶²Big Data Institute at the Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK. ⁶³Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK. ⁶⁴Division of Cardiovascular Medicine and Abboud Cardiovascular Research Center, University of Iowa, Iowa City, IA, USA. ⁶⁵Synlab Academy, Synlab Holding Deutschland GmbH, Mannheim, Germany. ⁶⁶Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria. ⁶⁷Department of Internal Medicine, Clinical Sciences, Lund University and Skåne University Hospital, Malmö, Sweden. ⁶⁸Vanderbilt University School of Medicine, Nashville, TN, USA. ⁶⁹Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom. ⁷⁰Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria. ⁷¹National Institute for Health and Welfare, Helsinki, Finland. ⁷²Department of Medicine, Turku University Hospital and University of Turku, Turku, Finland. ⁷³TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA. ⁷⁴Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. ⁷⁵Department of Medicine, Epidemiology, and Health Services, University of Washington, Seattle, WA, USA. ⁷⁶Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, USA. ⁷⁷The Institute for Translational Genomics and Population Sciences, Departments of Pediatrics and Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA. ⁷⁸Department of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands. ⁷⁹Division of Cardiology, Department of Medicine, University of Pittsburgh Medical Center and VA Pittsburgh HCS, Pittsburgh, PA, USA. ⁸⁰Department of Epidemiology, University of Washington, Seattle, WA, USA. ⁸¹Seattle Epidemiologic Research and Information Center, Department of Veterans Affairs Office of Research & Development, Seattle, WA, USA. ⁸²Department of Clinical Biochemistry, Copenhagen University Hospital, Herlev and Gentofte, København, Denmark. ⁸³Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom. ⁸⁴Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden. ⁸⁵Department of Cardiology, Södersjukhuset, Stockholm, Sweden. ⁸⁶Institute for Translational Genomics and Population Sciences, LABiomed and Departments of Pediatrics at Harbor-UCLA Medical Center, Torrance, CA 90502, USA. ⁸⁷Division of Cardiology, Department of Internal Medicine, Landspítali, National University Hospital of Iceland, Hringbraut, 101 Reykjavik, Iceland. ⁸⁸Faculty of Medicine, Department of Medicine, University of Iceland, Saemundargata 2, 101, Reykjavik, Iceland. ⁸⁹Department of Epidemiology and Biostatistics, Aalborg University Hospital, Aalborg, Denmark. ⁹⁰Department of Health, Science and Technology, Aalborg University Hospital, Aalborg, Denmark. ⁹¹Departments of Cardiology, Aalborg University Hospital, Aalborg, Denmark. ⁹²Section of Gerontology and Geriatrics, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands. ⁹³Translational and Clinical Research, Servier Cardiovascular Center for Therapeutic Innovation, 50 rue Carnot, 92284 Suresnes, France. ⁹⁴Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. ⁹⁵Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany. ⁹⁶Human Genetics, GlaxoSmithKline, Collegeville, PA, USA. ⁹⁷Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, OH, USA. ⁹⁸Université de Lorraine, CHU de Nancy, Inserm and INI-CRCT (F-CRIN), Institut Lorrain du Coeur et des Vaisseaux, 54500 Vandoeuvre Lès, Nancy, France. ⁹⁹BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom. ¹⁰⁰Queensland Brain Institute, The University of Queensland, Brisbane, QLD 4072, Australia. ¹⁰¹Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA. ¹⁰²Cardiac Arrhythmia Service and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA. ¹⁰³Medical Research Council Population Health Research Unit at the University of Oxford, Oxford, UK. ¹⁰⁴Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, Big Data Institute, University of Oxford, Oxford, UK. ¹⁰⁵National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospital, Oxford, UK. ¹⁰⁶Division of Psychiatry, University College of London, London W1T 7NF, UK. ¹⁰⁷UCL Genetics Institute, University College London, London WC1E 6BT, UK. ¹⁰⁸Department of Cardiology, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden. ¹⁰⁹Wallenberg Center for Molecular Medicine and Lund University Diabetes Center, Lund University, Lund, Sweden. ¹¹⁰Sections of Cardiology, Preventive Medicine and Epidemiology, Department of Medicine, Boston University Schools of Medicine and Public Health, Boston, MA, USA. ¹¹¹Bart's Heart Centre, St. Bartholomew's Hospital, London, UK. ¹¹²These authors contributed equally: Sonia Shah, Albert Henry. A full list of consortium members appears at the end of the paper. *email: t.lumbers@ucl.ac.uk

Regeneron Genetics Center

Goncalo Abecasis²², Joshua Backman²², Xiaodong Bai²², Suganthi Balasubramanian²², Nilanjana Banerjee²², Aris Baras²², Leland Barnard²², Christina Beechert²², Andrew Blumenfeld²², Michael Cantor²², Yating Chai²², Jonathan Chung²², Giovanni Coppola²², Amy Damask²², Frederick Dewey²², Aris Economides²², Gisu Eom²², Caitlin Forsythe²², Erin D. Fuller²², Zhenhua Gu²², Lauren Gurski²², Paloma M. Guzzardo²², Lukas Habegger²², Young Hahn²², Alicia Hawes²², Cristopher van Hout²², Marcus B. Jones²², Shareef Khalid²², Michael Lattari²², Alexander Li²², Nan Lin²², Daren Liu²², Alexander Lopez²², Kia Manoochehri²², Jonathan Marchini²²,

Anthony Marcketta²², Evan K. Maxwell²², Shane McCarthy²², Lyndon J. Mitnau²², Colm O'Dushlaine²², John D. Overton²², Maria Sotiropoulos Padilla²², Charles Paulding²², John Penn²², Manasi Pradhan²², Jeffrey G. Reid²², Thomas D. Schleicher²², Claudia Schurmann²², Alan Shuldiner²², Jeffrey C. Staples²², Dylan Sun²², Karina Toledo²², Ricardo H. Ulloa²², Louis Widom²², Sarah E. Wolf²², Ashish Yadav²² & Bin Ye²²